Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00094991

Enrollment

Registered

2004-11-01

Start date

2004-05-31

Completion date

2006-05-31

Last updated

2010-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Type 2 diabetes

Brief summary

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Interventions

DRUGMuraglitazar

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes; * Serum triglyceride concentration \< or = 600 mg/dL; * Body mass index \< or = 37 kg/m2

Exclusion criteria

* Type 1 diabetes; * History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months; * Congestive heart failure (NYHA Class III and IV); * Uncontrolled hypertension; * Women of Child Bearing Potential * History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease

Design outcomes

Primary

Measure	Time frame
The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar	—

Countries

Italy, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026